PMID- 29938870
OWN - NLM
STAT- MEDLINE
DCOM- 20180918
LR  - 20210109
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 109
IP  - 9
DP  - 2018 Sep
TI  - Survival analysis of multiple peptide vaccination for the selection of correlated 
      peptides in urological cancers.
PG  - 2660-2669
LID - 10.1111/cas.13709 [doi]
AB  - Peptide-based cancer vaccines are able to induce strong immune responses, but 
      their clinical results are unsatisfactory. To determine clinically correlated 
      peptides, we analyzed survival data from urological cancer patients treated by 
      personalized peptide vaccination (PPV), in which different multiple peptides were 
      used for individual patients based on human leukocyte antigen (HLA) type and 
      pre-existing immunity. Survival data were obtained from a database of 265 
      urological cancer patients treated in 5 clinical PPV trials comprising 154 
      patients with castration-resistant prostate cancer (CRPC) and 111 patients with 
      advanced urothelial cancer (UC). Expression of tumor-associated antigens (TAA) 
      was evaluated in 10 prostate cancer tissues, 4 metastatic lymph nodes from 
      prostate cancer, and 10 UC tissues using immunohistochemical staining. Clinical 
      efficacy of individual peptides for overall survival was evaluated by the Cox 
      proportional hazards regression model. All TAA coding candidate peptides used in 
      PPV treatment were expressed in tumor cells from prostate cancer and UC samples 
      except for p56Lck in both, and prostate-specific antigen (PSA), prostatic acid 
      phosphatase (PAP) and prostate-specific membrane antigen (PSMA) in the UC 
      samples. Patients with the following peptides had a significantly longer survival 
      than patients without the peptides (hazard ratio <1.0, 95% confidence intervals 
      <1.0 and P < .05): SART3-109, PTHrP-102, HNPRL-140, SART3-302 and Lck-90 in CRPC 
      patients, and EGF-R-800, Lck-486, PSMA-624, CypB-129 and SART3-734 in advanced UC 
      patients, respectively. Correlated peptides selected using both survival data and 
      pre-existing immunity for PPV treatment may enhance the clinical benefits for 
      urological cancer patients.
CI  - (c) 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Noguchi, Masanori
AU  - Noguchi M
AUID- ORCID: 0000-0003-2328-4985
AD  - Cancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan.
FAU - Koga, Noriko
AU  - Koga N
AD  - Cancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan.
FAU - Moriya, Fukuko
AU  - Moriya F
AD  - Department of Pathology, Kurume University School of Medicine, Kurume, Japan.
FAU - Suekane, Shigetaka
AU  - Suekane S
AUID- ORCID: 0000-0003-1150-2893
AD  - Department of Urology, Kurume University School of Medicine, Kurume, Japan.
FAU - Yutani, Shigeru
AU  - Yutani S
AUID- ORCID: 0000-0001-6306-4130
AD  - Cancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan.
FAU - Yamada, Akira
AU  - Yamada A
AD  - Division of Cancer Vaccines in Research Center for Innovative Cancer Therapy, 
      Kurume University School of Medicine, Kurume, Japan.
FAU - Shichijo, Shigeki
AU  - Shichijo S
AUID- ORCID: 0000-0003-4797-0429
AD  - Cancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan.
FAU - Kakuma, Tatuyuki
AU  - Kakuma T
AD  - Bio-statistics Center, Kurume University School of Medicine, Kurume, Japan.
FAU - Itoh, Kyogo
AU  - Itoh K
AD  - Cancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180723
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Neoplasm/analysis
MH  - Cancer Vaccines/*immunology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Urologic Neoplasms/immunology/mortality/*therapy
MH  - *Vaccination
MH  - Vaccines, Subunit/immunology
PMC - PMC6277968
OTO - NOTNLM
OT  - immunotherapy
OT  - peptide-based cancer vaccine
OT  - prostate cancer
OT  - survival analysis
OT  - urothelial cancer
EDAT- 2018/06/26 06:00
MHDA- 2018/09/19 06:00
PMCR- 2018/09/01
CRDT- 2018/06/26 06:00
PHST- 2018/04/13 00:00 [received]
PHST- 2018/06/16 00:00 [accepted]
PHST- 2018/06/26 06:00 [pubmed]
PHST- 2018/09/19 06:00 [medline]
PHST- 2018/06/26 06:00 [entrez]
PHST- 2018/09/01 00:00 [pmc-release]
AID - CAS13709 [pii]
AID - 10.1111/cas.13709 [doi]
PST - ppublish
SO  - Cancer Sci. 2018 Sep;109(9):2660-2669. doi: 10.1111/cas.13709. Epub 2018 Jul 23.